How is iAluRil administered?

iAluRil is administered intravesically as a 50ml bladder instillation via a catheter (with Luer-Lock adapter) or using the iAluadapter®.
Self administration of iAluRil is permitted following appropriate training.

Administration using a catheter

  1. After the patient has urinated spontaneously, empty the bladder of all traces of urine by inserting a suitable sterile catheter through the external urethral meatus (use of an 8Ch catheter is recommended during this stage).
  2. Screw the plunger rod supplied with the prefilled syringe, until it is perfectly in place.
  3. Mount the Luer-Lock adapter on the top of the prefilled syringe and apply onto it the sterile catheter previously placed in the bladder.
  4. Instil all the solution contained in the syringe into the bladder through the catheter.
  5. Keep iAluRil in the bladder for between 30 minutes and 3 hours.

Administration using the iAluadapter

  1. Ask the patient to completely empty their bladder.
  2. Attach the iAluadapter onto the iAluRil pre-filled syringe using a no touch technique and a half-twist motion.
  3. Lubricate the tip by squeezing a small amount of iAluRil from the syringe to just sit on the tip of the iAluadapter.
  4. Insert the tip of the iAluadapter into the urethra; rotating to ensure a good fit.
  5. Enhance pressure on the syringe to slowly instil, reminding the patient to relax as much as possible.
  6. Keep iAluRil in the bladder for between 30 minutes and 3 hours.

Self-administration video for women

Self-administration video for men

Support is available to facilitate self-administration training for both male and female patients.

The iAluadapter is a small tip that attaches to the end of the iAluRil syringe.

It allows administration of iAluRil without the need for a catheter so enables treatment to more comfortably continue at home. It comes as standard in each iAluRil box.

  1. The end part fits securely to the iAluRil pre-filled syringe.
  2. The ribbed centrepiece provides a secure grip when fitting to the syringe.
  3. The concave isolating collar is made from a flexible material that adapts to the uretheral opening, facilitating instillation without leakage.
  4. The radiused tip part is the only part of the device to penetrate into the urethral opening. It is shaped to maximise effectiveness and ease of use.
  • Minimally invasive and practically pain free1
  • Time saving for you and your patients
  • Enables simultaneous treatment of the urethral and bladder mucosa
  • Low risk of infection2

Which patients are suitable for the iAluadapter?2

  • 98% of female patients and 100% of male patients.
    (After the administrator has become proficient in administration)
  • Patients who have a residual of 100ml or less.
  • Patients with a urethral opening you can clearly see.

Please note, administration of iAluRil using the iAluadapter should not be done in the 3 days after sexual intercourse.


iAluRil treatment begins with a course of instillations given once a week for the first month. From clinical trials, data has shown that further instillations can then be given at varying intervals dependent on the condition being treated.

Once the symptoms have improved, the interval between instillations can be increased slowly until you are happy that the regular doses are enough to keep symptoms under control. If the symptoms reoccur, the initial course of installations can be repeated in order to settle the symptoms down again.

Clinical efficacy Protocols


iAluadapter use assessment, Carol Edmunds (Urology Nurse Consultant), North West Anglia NHS Foundation Trust. 2018.

Lovasz, S. Minimally invasive device for intravesical instillation by urological syringe adapter (MID-ii U.S.A.) for catheter-free instillation therapy of the bladder in interstitial cystitis/bladder pain syndrome. International Journal of Urology (2019) 26 (Suppl. 1), 57–60

Damiano R et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur. Urol. 59(4), 645-651 (2011)

Cicione A et al. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre study. Can Urol Assoc J. 2014; 8(9-10): E721-7

Imperatore V et al, Intravesical administration of combined hyaluronic acid and chondroitin sulfate can improve symptoms in patients with refractory bacillus Calmette-Guerin-induced chemical cystitis: Preliminary experience with one-year follow-up. Arch Ital Urol Androl. 2018 Mar 31; 90(1): 11-14

Creta M et al. Intravesical instillation of hyaluronic acid and chondroitin sulfate for bacillus calmette-guerin induced chemical cystitis. Poster presentation P164, 85th SIU (Italian Society of Urology) 2012; October 21-24

Gacci M et al. Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Improves Symptoms of Post radiation Cystitis: Prospective Pilot Study. Clin Genitourin Cancer. Oct;14(5):444-449 (2016)

Giannessi C et al. Nocturia related to post radiation bladder pain can be improved by hyaluronic acid chondroitin sulphate. Eur Urol Suppl. 2014; 13; e592

Always read the label.

Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148.